Publications

Publications

Publications

Science Media

Filter

Reset

Presentations

A Combined Phase I/II Study of a Novel Bicycle Tumor-targeted Immune Cell Agonist® BT7480 in Patients with Nectin-4 Associated Advanced Malignancies

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with...

Modeling the cDC1 ex vivo and in vitro: Development and characterization of a conventional dendritic cell culture system for...

Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small...

Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell...

Microbiology Society Annual Meeting

Bicycle®: A novel therapeutic modality for SARS-CoV-2

Bicycles, bi-cyclic peptides, novel small molecule delivery systems for RNA therapeutics

01 09

First

Previous

Next

Last

Publications

Bioconjugate Chemistry

Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides

Journal of Medicinal Chemistry

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology

Molecular Cancer Therapeutics

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Journal for ImmunoTherapy of Cancer

BT7480, a Novel Fully Synthetic Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Induces Tumor Localized CD137 Agonism

Journal for ImmunoTherapy of Cancer

Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist

ACS Infectious Diseases

An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics

Molecular Cancer Therapeutics

MMAE delivery using the Bicycle toxin conjugate BT5528

Journal of Medicinal Chemistry

Identification and Optimization of EphA2-Selective Bicycles for Delivery of Cytotoxic Payloads

01 02

First

Previous

Next

Last

Investor Overview^→